-
近些年,随着PET/CT设备及心脏正电子示踪剂获得了不断地提升和改善,PET心肌血流灌注显像(PET-myocardial perfusion imaging,PET-MPI)在临床上的作用逐渐加强。心肌血流灌注量是指单位时间内通过单位质量心肌的血流容积,可用局部心肌血流量(myocardial blood flow,MBF)表示。心肌血流灌注为心肌组织提供氧和营养物质,是维持心肌存活和功能的必要条件,当冠状动脉狭窄或者心肌微血管床受损时,单位时间内通过局部心肌的绝对血流量也相应减少。PET-MPI的定量分析为心肌血流提供了参数评价标准,弥补了目测评价会出现因人而异结果的不足和冠脉左主干或三支均衡病变可能被漏诊的情况,PET-MPI可以无创、客观地发现早期灌注减低和储备功能受损,准确地对冠心病进行危险分层、预后评价和客观判断治疗效果等,为冠心病患者科学地制定个体化诊治方案、心脏的生理和病理生理学领域的活体无创性研究等提供重要信息,显示了PET-MPI在该领域的独特优势。
PET心肌灌注显像及其定量分析的研究进展
The research progress of myocardial perfusion and its quantitative analysis with PET
-
摘要: 近些年,随着PET/CT设备及心脏正电子示踪剂的快速发展,PET心肌血流灌注显像(PET-MPI)在临床上的作用逐渐加强。心肌血流灌注定量分析提供了心肌血流的客观评价标准,可以客观、准确地发现早期灌注异常,准确地对冠心病进行危险分层、预后评价和客观判断治疗效果,为冠心病临床诊治、心脏的生理和病理生理学领域的活体无创性研究提供重要信息。笔者就PET-MPI及其定量分析的研究进展进行综述。
-
关键词:
- 冠状动脉疾病 /
- 正电子发射断层显像术 /
- 体层摄影术,X线计算机 /
- 心肌血流灌注显像 /
- 心肌血流量
Abstract: With the improvement of positron emission computed tomography (PET/CT) devices and the availability of cardiac positron tracers, the clinical interest in myocardial perfusion PET(PET-MPI) has increased over the years. PET-MPI enables noninvasive and accurate quantification of myocardial blood flow(MBF) and myocardial flow reserve(MFR), making it possible to enhance detection of early stages of vascular dysfunction, improve risk stratification of coronary heart disease, guide clinical management, evaluate efficacy and prognosis. The aim of this narrative review was to summarize the progress of cardiac PET for myocardial perfusion and its quantitative analysis. -
[1] Demer LL, Gould KL, Goldstein RA, et al. Assessment of coronary artery disease severity by position emission tomography. Comparison with quantitative arteriography in 193 patients[J]. Circulation, 1989, 79(4):825-835. DOI:org/10.1161/01.CIR.79.4. 825. [2] Tamaki N, Ruddy TD, Dekamp R, et al. Myocardial perfusion[M]//Wahl RL, Buchanan JW. Principles and Practice of Positron Emission Tomography. Philadelphia:Lippincott, Williams & Wilkins, 2002:320-333. [3] Sampson UK, Dorbala S, Limaye A, et al. Diagnostic accuracy of rubidium-82 myocardial perfusion imaging with hybrid positron emission tomography/computed tomography in the detection of coronary artery disease[J]. J Am Coll Cardiol, 2007, 49(10):1052-1058. DOI:10.1016/j.jacc.2006.12.015. [4] J Epstein N, Benelfassi A, SB Beanlands R, et al. An 82Rb infusion system for quantitative perfusion imaging with 3D PET[J]. Appl RadiatIsot, 2004, 60(6):921-927. DOI:10.1016/j.apradiso.2004. 02.002. [5] Anagnostopoulos C, Almonacid A, El Fakhri G, et al. Quantitative relationship between coronary vasodilator reserve assessed by 82Rb PET imaging and coronary artery stenosis severity[J]. Eur J Nucl Med Mol Imaging, 2008, 35(9):1593-1601. DOI:10.1007/s00259-008-0793-2. [6] Uren NG, Melin JA, De Bruyne B, et al. Relation between myocardial blood flow and the severity of coronary-artery stenosis[J]. N Engl J Med, 1994, 330(25):1782-1788. DOI:10.1056/NEJM199406233302503. [7] Di Carli M, Czernin J, Hoh CK, et al. Relation among stenosis severity, myocardial blood flow, and flow reserve in patients with coronary artery disease[J]. Circulation, 1995, 91(7):1944-1951. DOI:org/10.1161/01.CIR.91.7.1944. [8] Lubberink M, Harms HJ, Halbmeijer R, el al. Low-Dose Quantitative Myocardial Blood Flow Imaging Using 15O-Water and PET Without Attenuation Correction[J]. J NuclMed, 2010, 51(4):575-580. DOI:10.2967/jnumed.109.070748. [9] 李帅, 李剑明. 18F标记新型正电子心肌灌注显像剂的研究进展[J].中国医学影像技术, 2014, 30(6):926-929.Li
Li S, Li JM. Progresses of new myocardial perfusion imaging agents labeled with 18F[J]. Chin J Med Imaging Technol, 2014, 30(6):926-929.[10] Berman DS, Germano G, Slomka PJ. Improvement in PET myocardial perfusion image quality and quantification with flurpiridaz 18F[J]. J Nucl Cardiol, 2012, 19 Suppl 1:S38-45. DOI:10.1007/s12350-011-9487-4. [11] 彭程, 赵祚全, 陈淑婷, 等. 18F标记的新型鏻正阳离子PET心肌灌注显像剂的制备及生物性能评价[J].同位素, 2014, 27(4):223-229. DOI:10.7538/tws.2014.27.04.0223.
Peng C, Zhao ZQ, Chen ST, et al. Preparation and biological evaluation of novel 18F-labeled phosphonuimcation for myocardial perfusion imaging with PET[J]. J Isotopes, 2014, 27(4):223-229. doi: 10.7538/tws.2014.27.04.0223[12] 王道宇, 牟甜甜, 赵祚全, 等.新型18F标记心肌灌注显像剂的PET显像实验研究[J].中国医学装备, 2015, 12(6):50-53. DOI:10.3969/J.ISSN.1672-8270.2015.06.016.
Wang DY, Mou TT, Zhao ZQ, et al. The preliminary experimental study of a novel 18F-labeled myocardial perfusion imaging agent for PET imaging[J]. China Med Equipment, 2015, 12(6):50-53. doi: 10.3969/J.ISSN.1672-8270.2015.06.016[13] 汪娇, 李剑明. PET/CT正电子心肌灌注显像剂的研究进展[J].中国医学影像学杂志, 2014, 138(11):877-880. DOI:10.3969/j.issn.1005-5185.2014.11.021.
Wang J, Li JM. Research progress of PET/CT myocardial perfusion imaging agent[J]. Chin J Med Imaging, 2014, 138(11):877-880. doi: 10.3969/j.issn.1005-5185.2014.11.021[14] Yu M, Guaraldi MT, Mistry M, et al. BMS-747158-02:a novel PET myocardial perfusion imaging agent[J]. J Nucl Cardiol, 2007, 14(6):789-798. DOI:10.1016/j.nuclcard.2007.07.008. [15] Maddahi J, Czernin J, Lazewatsky J, et al. Phase Ⅰ, first-in-human study of BMS747158, a novel 18F-labeled tracer for myocardial perfusion PET:dosimetry, biodistribution, safety, and imaging characteristics after a single injection at rest[J]. J Nucl Med, 2011, 52(9):1490-1498. DOI:10.2967/jnumed.111.092528. [16] Uren NG, Crake T, Lefroy DC, et al. Reduced coronary vasodilator function in infarcted and normal myocardium after myocardial infarction[J]. N Engl J Med, 1994, 331(4):222-227. DOI:10.1056/NEJM199407283310402. [17] Parkash R, Dekemp RA, Ruddy TD, et al. Potential utility of Rubidium 82 PET quantification in patients with 3-vessel coronary artery disease[J]. J NuclCardiol, 2004, 11(4):440-449. DOI:10.1016/j. nuclcard.2004.04.005. [18] Yoshinaga K, Katoh C, Manabe O, et al. Incremental diagnostic value of regional myocardial blood flow quantifcation over relative perfusion imaging with generator-produced rubidium-82 PET[J]. Circ J, 2011, 75(11):2628-2634. DOI:org/10.1253/circj.CJ-11-0502. [19] Fiechter M, Ghadri JR, Gebhard C, et al. Diagnostic value of 13N-ammonia myocardial perfusion PET:added value of myocardial flow reserve[J]. J Nucl Med, 2012, 53(8):1230-1234. DOI:10.2967/jnumed.111.101840. [20] Yoshinaga K, Tomiyama Y, Tamaki N, et al. Myocardial blood flow quantification using positron-emission tomography:analysis and practicein the clinical setting[J]. Circ J, 2013, 77(7):1662-1671. DOI:10.1253/circj.CJ-13-0235. [21] 田丛娜, 魏红星, 张晓丽. PET心肌灌注显像测定心肌血流量及冠状动脉血流储备的研究进展[J].国际放射医学核医学杂志, 2012, 36(5):274-279. DOI:10.3760/cnla.j.issn.1673-4114. 2012. 05.004.
Tian CN, Wei HX, Zhang XL. Progress of myocardial blood flow and coronary flow reserve measurement using PET myocardial perfusion imaging[J]. Int J Radiat Med Nucl Med, 2012, 36(5):274-279. doi: 10.3760/cnla.j.issn.1673-4114.2012.05.004[22] Patel MR, Bailey SR, Bonow RO, et al. ACCF/SCAI/AATS/AHA/ASE/ASNC/HFSA/HRS/SCCM/SCCT/SCMR/STS 2012 Appropriate Use Criteria for Diagnostic Catheterization:A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Society for Cardiovascular Angiography and Interventions, American Association for Thoracic Surgery, American H eart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons[J]. J Am Coll Cardiol, 2012, 59(22):1995-2027. DOI:10.1016/j.jacc.2012. 03.003. [23] Patel MR, Dehmer GJ, Hirshfeld JW, et al. ACCF/SCAI/STS/AATS/AHA/ASNC/HFSA/SCCT 2012 Appropriate use criteria for coronary revascularization focused update:a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, American Society of Nuclear Cardiology, and the Society of Cardiovascular Computed Tomography[J]. J Am Coll Cardiol, 2012, 59(9):857-881. DOI:10.1016/j.jacc.2011.12.001. [24] Di Carli MF, Dorbala S. Integrated PET/CT for cardiol imaging[J]. Q J Nucl Med Mol Imaging, 2006, 50(1):44-52. [25] Beanlands RS, Dekemp RA, Smith S, et al. F-18-Fluorodeoxyglucose PET imaging alters clinical decision making in patients with impaired ventricular function[J]. Am J Cardiol, 1997, 79(8):1092-1095. DOI:10.1016/S0002-9149(97)00054-4. [26] Taqueti VR, Hachamovitch R, Murthy VL, et al. Global coronary flow reserve is associated with adverse cardiovascular events independently ofluminal angiographic severity and modifies the effectof early revascularization[J]. Circulation, 2015, 131(1):19-27. DOI:10.1161/CIRCULATIONAHA.114.011939. [27] Dorbala S, Di Carli MF. Cardiac PET perfusion:prognosis, risk stratification, and clinical management[J]. Semin Nucl Med, 2014, 44(5):344-357. DOI:10.1053/j.semnuclmed.2014.05.003. [28] Dorbala S, Di Carli MF, Beanlands RS, et al. Prognostic value of stress myocardial perfusion positron emission tomography:results from a multicenter observational registry[J]. J Am CollCardiol, 2013, 61(2):176-184. DOI:10.1016/j.jacc.2012.09.043. [29] Dorbala S, Hachamovitch R, Curillova Z, et al. Incremental prognostic value of gated Rb-82 positron emission tomography myocardial perfusion imaging over clinical variables and rest LVEF[J]. JACC Cardiovasc Imaging, 2009, 2(7):846-854. DOI:10.1016/j.jcmg.2009.04.009. [30] Farhad H, Dunet V, Bachelard K, et al. Added prognostic value of myocardial blood flow quantitation in rubidium-82 positron emission tomography imaging[J]. Eur Heart J Cardiovasc Imaging, 2013, 14(12):1203-1210. DOI:10.1093/ehjci/jet068. [31] Valenta I, Quercioli A, Vincenti G, et al. Structuralepicardial disease and microvascular function are determinants of an abnormal longitudinal myocardial blood flow difference in cardiovascular risk individuals as determined with PET/CT[J]. J Nucl Cardiol, 2010, 17(6):1023-1033. DOI:10.1007/s12350-010-9272-9. [32] De Bruyne B, Hersbach F, Pijls NH, et al. Abnormalepicardial coronary resistance in patients with diffuse atherosclerosis but "Normal" coronary angiography[J]. Circulation, 2001, 104(20):2401-2406. doi: 10.1161/hc4501.099316 [33] Valenta I, Wahl RL, Schindler TH. Longitudinal myocardial blood flow gradient and CAD detection[J]. Curr Cardiol Rep, 2015, 17(1):550. DOI:10.1007/s11886-014-0550-z. [34] Valenta I, Quercioli A, Schindler TH, et al. Diagnostic value of PET-Measured longitudinal flow gradient for the identification of coronary artery disease[J]. JACC Cardiovasc Imaging, 2014, 7(4):387-396. DOI:10.1016/j.jcmg.2014.01.001. [35] Lanza GA, Crea F. Primary coronary microvascular dysfunction:clinical presentation, pathophysiology, and management[J]. Circulation, 2010, 121(21):2317-2325. DOI:10.1161/CIRCULATI ONAHA.109.900191. [36] Leung DY, Leung M. Non-invasive/invasive imaging:significance and assessment of coronary microvasculardysfunction[J]. Heart, 2011, 97(7):587-595. DOI:10.1136/hrt.2009.183327. [37] Cecchi F, Olivotto I, Gistri R, et al. Coronarymicrovascular dysfunction and prognosis in hypertrophic cardiomyopathy[J]. N Engl J Med, 2003, 349(11):1027-1035. DOI:10.1056/NEJMoa025050. [38] Olivotto I, Cecchi F, Gistri R, et al. Relevance of coronary microvascular flow impairment to long-term remodeling and systolic dysfunction in hypertrophic cardiomyopathy[J]. J Am Coll Cardiol, 2006, 47(5):1043-1048. DOI:10.1016/j.jacc.2005.10.050. [39] Castagnoli H, Ferrantini C, Coppini R, et al. Role of quantitative myocardial positron emission tomography for risk stratification in patients with hypertrophic cardiomyopathy:a 2016 reappraisal[J]. Eur J Nucl Med Mol Imaging, 2016, 43(13):2413-2422. DOI:10.1007/s00259-016-3465-7.
计量
- 文章访问数: 3454
- HTML全文浏览量: 2569
- PDF下载量: 5